Summit Trail Advisors’s Editas Medicine EDIT Stock Holding History

Summit Trail Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-11	Closed	–	–	781
2017 Q4	$0	Buy	+11	New	+$277	﹤0.01%	1999

Other funds holding EDIT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Summit Trail Advisors's EDIT Position: Q1 2018 in Review

Summit Trail Advisors sold out of Editas Medicine (EDIT) in Q1 2018, closing a stake of 11 shares.

Summit Trail Advisors first reported a position in EDIT in Q4 2017 and held it in 1 quarter. The position peaked at $0 in Q4 2017. 197 funds tracked by Wall St. Rank hold EDIT as of Q1 2018.

Summit Trail Advisors reported no remaining Editas Medicine position as of Q1 2018 after selling out during the quarter.
Summit Trail Advisors sold 11 Editas Medicine shares in Q1 2018.
Summit Trail Advisors first reported a position in Editas Medicine in Q4 2017 and held it in 1 quarter.
Summit Trail Advisors's Editas Medicine position peaked at $0 in Q4 2017.
197 funds tracked by Wall St. Rank held Editas Medicine as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.